Development of a broad spectrum polymer-released antimicrobial coating for the prevention of resistant strain bacterial infections

作者：Sinclair K D^*; Pham T X; Farnsworth R W; Williams D L; Loc Carrillo C; Horne L A; Ingebretsen S H; Bloebaum R D

来源：Journal of Biomedical Materials Research Part A, 2012, 100A(10): 2732-2738.

DOI：10.1002/jbm.a.34209

• ceragenin
• CSA-13
• antimicrobial agents
• drug delivery
• controlled release device

More than 400,000 primary hip and knee replacement surgeries are performed each year in the United States. From these procedures, approximately 0.53% will become infected and when considering revision surgeries, this rate has been found to increase significantly. Antibiotic-resistant bacterial infections are a growing problem in patient care. This in vitro research investigated the antimicrobial potential of the polymer released, broad spectrum, Cationic Steroidal Antimicrobial-13 (CSA-13) for challenges against 5 x 108 colony forming units (CFU) of methicillin-resistant Staphylococcus aureus (MRSA). It was hypothesized that a weight-to-weight (w/w) concentration of 18% CSA-13 in silicone would exhibit potent bactericidal potential when used as a controlled release device coating. When incorporated into a polymeric device coating, the 18% (w/w) broad-spectrum polymer released CSA-13 antimicrobial eliminated 5 x 108 CFU of MRSA within 8 h. In the future, these results will be utilized to develop a sheep model to assess CSA-13 for the prevention of perioperative device-related infections in vivo. Published 2012 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 100A: 2732-2738, 2012.

• 出版日期2012-10